TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
In this study presented at the American Society of Clinical [...]
ASCO GU 2023: Further information from the cabozantinib plus nivolumab study
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer
Non-clear cell kidney cancer is a group of different subtypes [...]
Real-world survival outcomes of metastatic papillary and clear cell kidney cancer
In this study, real world data is used to compare [...]
Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer
A recent paper published in The Oncologist has shown that [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
Shared decision-making in kidney cancer
Over 400,000 people are diagnosed with kidney cancer globally each [...]
